N

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Senior Scientist / Principal Scientist - Induced Proximity

Translational Research & Bench BiologyConfirmed live in the last 24 hours
Full-timeBrisbane, CA, USA$162k - $208.6k

About the Job

Requirements

  • A Ph.D. in biology, biochemistry, molecular biology, or a related field.
  • At least 5 years of relevant industry drug discovery experience, including significant direct work on induced proximity modalities such as targeted protein degradation, molecular glues, bifunctional degraders, or similar approaches.
  • Hands-on biophysical and biochemical assay development to quantify ternary complex formation and cooperativity, using methods such as TR-FRET/HTRF, NanoBRET, AlphaLISA, SPR, ITC, MST, or DSF.
  • Experience developing biochemical assays for relevant proximity-induced reactions such as ubiquitination, phosphorylation, or acetylation.
  • Cell-based mechanistic pharmacology experience, including Western blot, HiBiT/NanoLuc kinetic readouts, flow cytometry, reporter assays, and dose-response and washout/resynthesis studies to establish on-target mechanism.
  • Experience with cell line engineering and functional genomics using CRISPR knockout/knock-in, CRISPRa/CRISPRi, and siRNA to validate targets and interrogate effector dependencies.
  • Experience with target engagement and protein-stability methods, including CETSA, NanoBRET target engagement, co-IP/pulldown, and cycloheximide-chase or half-life measurement.
  • Deep mechanistic understanding of ternary complex biology and cooperativity, the ubiquitin-proteasome and autophagy-lysosomal pathways, non-degradative proximity mechanisms, and structure-based drug design.
  • Rigorous experimental design and quantitative data analysis, including assay qualification and quality control such as Z′ and dynamic range, curve fitting in GraphPad Prism or equivalent, screening-data handling in Genedata Screener or similar, and disciplined electronic lab notebook documentation.
  • A strong track record of cross-functional collaboration across biology, chemistry, and DMPK.
  • Scientific communication skills, including experience presenting to senior leadership.

Responsibilities

  • Design, execute, and troubleshoot bench experiments, including building and running biochemical, biophysical, and cell-based assays to interrogate induced proximity mechanisms and drive program decisions.
  • Contribute to identifying, validating, and prioritizing targets amenable to induced proximity approaches, including protein sequestration, gene regulation, stabilizers, and related mechanisms.
  • Evaluate and integrate new and emerging induced proximity modalities into the strategic roadmap.
  • Partner with computational and structural biology teams to advance rational design and predictive modeling of ternary complex formation.
  • Present experimental data, interpretations, and recommendations to project teams and executive leadership.
  • Ensure programs meet key milestones from discovery through candidate nomination and IND-enabling work.
  • Stay current on the competitive and scientific landscape, and publish or present externally as needed to build company visibility.

Desired Qualifications

  • A Ph.D. in a relevant scientific field such as biochemistry, biology, or chemical biology with at least 4 years of relevant postgraduate industry or academic research experience, or an MS with at least 8 years of relevant industry experience.
  • A publication record and/or patents in induced proximity or targeted degradation.
  • Experience with computational tools for ternary complex prediction or AI/ML-driven drug design.
  • Familiarity with a broad range of non-degradative modalities beyond classical bifunctional degraders, such as glues, LYTACs, AUTACs, MrTACs, RIPTACs, TCIPs, Tracers, and DACs.

About the Company

Nurix Therapeutics

Drug discovery targeting ubiquitin E3 ligases

Nurix Therapeutics develops drugs that use the body's own protein-degradation system to treat diseases. Its core approach is to control ubiquitin E3 ligases, enzymes that tag unwanted proteins for breakdown in cells. By modulating these ligases, Nurix aims to create therapeutics, especially small-molecule immuno-oncology agents, that can selectively remove disease-related proteins in cancer and other serious conditions. The company operates by discovering and developing drug candidates and earning revenue through partnerships, licensing, and potential future sales of its medicines. Unlike many biotech firms that target single proteins, Nurix focuses on the protein-degradation pathway to influence multiple disease processes through carefully designed molecules. The goal is to bring new cancer treatments and other therapies to patients by advancing its degrader-based drugs through research, collaboration, and development toward commercial use.

Company size
201-500
Company stage
IPO
Headquarters
Brisbane, CA
Founded
2012

Recently Posted Jobs

Explore more opportunities at Nurix Therapeutics

See more jobs